Setback for Moderna as court upholds Arbutus patent

24 July 2020

After a run of positive announcements on the clinical side, mRNA therapeutics and vaccines developer Moderna Therapeutics (Nasdaq: MRNA) has been struck with a patent blow, knocking 10% off its share price.

A ruling from the US Patent and Trademark Office (USPTO) has found that an Arbutus Biopharma (Nasdaq: ABUS) patent should not be revoked, as the firm had requested.

Moderna argued the patent, which relates to lipid nanoparticle (LNP) technology, should be annulled as being too obvious.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK